Biotech hedge fund analyst pitches new immunology company — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Mohit Gupta, an analyst working for Dan Schneeberger at biotech hedge fund Adar1 Capital, pitched the company-building idea two years ago at Schneeberger's Austin, Texas office
- The proposed company's goal is to develop a long-acting antibody treatment for atopic dermatitis, a chronic skin condition
- Dan Schneeberger's day job is investing in biotech companies that are already developing drugs, not starting new ones from scratch
- The story appeared in Adam's Biotech Scorecard, a STAT+ subscriber-only newsletter
Why it matters: For Adar1 Capital's Dan Schneeberger—who normally invests in biotech companies already developing drugs—the pitch to build a new atopic dermatitis antibody company from scratch represents a rare departure from the fund's standard playbook of buying into existing developers.
Ask SkimNews
